Contrast-associated Acute Kidney Injury
Conditions
Keywords
Acute kidney injury, contrast media, tomography, ontrast-induced nephropathy
Brief summary
Rationale and objectives: Since 1930 it has been accepted that intravenous injection of io-dinated contrast agent as part of contrast-enhanced computed tomography (CE-CT) imaging can induce a contrast-associated acute kidney injury (CA-AKI). For the last 10 years, studies have investigated this iatrogenia. However, those works didn't concern French population and particularly patient hospitalised after emergency department (ED) visit. This study as-sessed the CA-AKI incidence and factor risks in patients hospitalised after a CE-CT in ED. This was a retrospective cohort observational study in the ED of the Beaujon University Hospital between October 31st 2019 to January 24th 2022. Patients over 16 years old who presented to the emergency department and underwent an intravenous contrast-enhanced CT were eligible. To be included, patients were required to have at least two creatinine measurements: one taken within 24 hours before CT and a second measurement taken between 48 hours to the seventh day following the initial test. The CT examination had to be performed at Beaujon Hospital with the injection of iodinated contrast agents such as IOMERON® (iomeprol) or XENETIX® (iobitridol).
Interventions
OTHERthere is no intervention
NO INTERVENTION
Sponsors
Beaujon Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
16 Years to No maximum
Inclusion criteria
* Patients over 16 years old who presented to the emergency department and underwent an intravenous contrast-enhanced CT were eligible. To be included, patients were required to have at least two creatinine measurements: one taken within 24 hours before CT and a sec-ond measurement taken between 48 hours to the seventh day following the initial test. The CT examination had to be performed at Beaujon Hospital with the injection of iodinated contrast agents such as IOMERON® (iomeprol) or XENETIX® (iobitridol).
Exclusion criteria
* Patients were excluded from the study if they did not have two creatinine measurements meeting the specified criteria. If multiple contrast-enhanced CT examinations were per-formed within a seven-day period for the same patient, only the first examination was in-cluded in the study, while subsequent scans were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was the occurrence of CA-AKI defined as KDIGO (Kidney Disease Improval Global Outcomes) tage 1 or higher within seven days after contrast-enhanced CT. | BETWEEN 2 and 7 DAYS ATER CT -SCAN |
Countries
France
Outcome results
None listed